From Wikipedia, the free encyclopedia
Chemical compound
Ocedurenone, formerly known as KBP-5074,
[1] is a nonsteroidal, selective
mineralocorticoid receptor antagonist that is being developed to treat
hypertension in patients with
chronic kidney disease with less risk of
hyperkalemia than existing treatments.
[2]
[3] In 2023, KPB Biosciences entered in talks to sell the drug to
Novo Nordisk for USD$1.3 billion. It is a
small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.
[4]
[5]
References
-
^
"Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.
-
^ Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021).
"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023.
doi:
10.1080/13543784.2021.1985462.
ISSN
1744-7658.
-
^ Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021).
"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81.
doi:
10.1161/HYPERTENSIONAHA.121.17073.
PMC
8189259.
-
^
"Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. Retrieved 4 November 2023.
-
^
"Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.